Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$0.12.

  • Marker Therapeutics' EPS (Basic) rose 5384.62% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.23, marking a year-over-year decrease of 1388.89%. This contributed to the annual value of -$1.2 for FY2024, which is 28122.02% down from last year.
  • According to the latest figures from Q3 2025, Marker Therapeutics' EPS (Basic) is -$0.12, which was up 5384.62% from -$0.29 recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' EPS (Basic) peaked at -$0.01 during Q4 2023, and registered a low of -$1.19 during Q1 2022.
  • Its 4-year average for EPS (Basic) is -$0.39, with a median of -$0.29 in 2025.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 9841.23% in 2023, then tumbled by 580352.63% in 2024.
  • Marker Therapeutics' EPS (Basic) (Quarter) stood at -$0.45 in 2022, then skyrocketed by 98.41% to -$0.01 in 2023, then tumbled by 5803.53% to -$0.42 in 2024, then surged by 71.55% to -$0.12 in 2025.
  • Its last three reported values are -$0.12 in Q3 2025, -$0.29 for Q2 2025, and -$0.4 during Q1 2025.